comparemela.com
  1. Home
  2. Live Updates
  3. Treatment Diabetic Retinopathy Study - Breaking News

Latest Breaking News On - Treatment diabetic retinopathy study - Page 1 : comparemela.com

Extended Anti-VEGF Treatment Intervals Improve Best VA in DME

Extended anti-VEGF treatment intervals requiring less injections than indicated in clinical trials improve VA in patients with DME.

Treatment diabetic retinopathy study

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

51 wet AMD patients with severe disease activity and high treatment burden were randomized to high or low dose 4D-150 or aflibercept control regimen4D-150 was well tolerated with a favorable.

United statesArshadm khananiDavid kirnRobert kimJulian peiKatherine smithCorporate communicationsProgram updatesExchange commissionGlobenewswire incClinical data programEuropean unionClinic researchSierra eye associatesD molecular therapeutics incMolecular therapeutics

4DMT Presents Positive Interim Data from Randomized Phase 2

51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden.

United statesDavid kirnKatherine smithRobert kimJulian peiArshadm khananiClinic research at sierra eye associatesProgram updatesEuropean unionCorporate communicationsClinical data programExchange commissionMolecular therapeuticsChief executive officerChief medicalClinic research

4DMT Presents Positive Interim Data From Randomized Phase 2 PRISM Clinical Trial Of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinica

4DMT Presents Positive Interim Data From Randomized Phase 2 PRISM Clinical Trial Of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinica
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesDavid kirnRobert kimArshadm khananiProgram updatesClinic research at sierra eye associatesMolecular therapeuticsChief executive officerChief medical officerClinic researchSierra eye associatesTrial dose expansion cohort backgroundSummary baseline characteristicsDose expansionInterim resultsTreatment diabetic retinopathy study

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesJulian peiRobert kimDavid kirnArshadm khananiKatherine smithProgram updatesClinic research at sierra eye associatesCorporate communicationsEuropean unionClinical data programExchange commissionPositive interim dataRandomized phaseFavorable tolerabilityClinical activity
© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.